Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic
27 Mayo 2024 - 4:00AM
Helsinn and Angelini Pharma sign a partnership agreement renewal to
commercialize AULIN® and MESULID® in Bulgaria, Czech Republic,
Hungary, Poland, Romania and Slovak Republic
Helsinn and Angelini Pharma sign a
partnership agreement renewal to commercialize
AULIN® and
MESULID® in Bulgaria, Czech
Republic, Hungary, Poland, Romania and Slovak Republic
Lugano (Switzerland) and Rome (Italy)–
May 27, 2024 – Helsinn Group (“Helsinn”), a global
pharmaceutical company with a track record of over forty-five years
of commercial execution and a strong focus in supportive care,
oncology and dermato-oncology, and Angelini Pharma (“Angelini”), an
international pharmaceutical company, part of the Italian
privately-owned multi-business Angelini Industries, that
researches, develops and commercializes health solutions with a
focus on the areas of Brain Health, including Mental Health and
Epilepsy, and Consumer Health, announce today the signing of the
Distribution and Licence Agreement renewal in Bulgaria, Czech
Republic, Hungary, Poland, Romania and Slovak Republic for AULIN®
and MESULID® (Nimesulide) for the treatment of acute (short-term)
pain.
Erik Lommerde, Executive VP
International Operations at Angelini Pharma,
remarked: “We are delighted to renew our
partnership with Helsinn. This collaboration is built on a
foundation of mutual trust, highlighted by our shared commitment to
professional excellence, in-depth product knowledge, and
high-quality service. This alliance is crucial for both parties and
represents a strong business relationship.”
Dr. Melanie Rolli, Helsinn Group CEO,
commented: “We are pleased to have signed this agreement
with Angelini and honored to maintain our ongoing collaboration.
Our long-standing partnership with Angelini exemplifies how Helsinn
fosters relationships and alliances to deliver essential products
to patients. We appreciate their extensive reach in these
countries, which enables patient access to this much needed
treatment.”
About AULIN®
MESULID®
The product is a non-selective, non-steroidal
anti-inflammatory drug (NSAID) and is available by prescription as
an oral tablet and granules for oral suspension. It is used as a
second line treatment for acute pain and primary dysmenorrhea.
Aulin® gel (other marketed brand names include: AulinDol®)
depending on the market, is available by prescription or over the
counter and is indicated for symptomatic relief of pain associated
with sprains and acute traumatic tendinitis. Further information is
available in the Summary of Product Characteristics which can be
provided upon request.
About Angelini
IndustriesAngelini Industries is a multinational
industrial group founded in Ancona in 1919 by Francesco Angelini.
Today, Angelini Industries represents a solid and diversified
industrial reality that employs approximately 5,800 employees and
operates in 21 countries around the world with revenues of over 2
billion euros, generated in the health, industrial technology, and
consumer goods sectors. A targeted investment strategy for growth;
constant commitment to research and development; deep knowledge of
markets and business sectors, make Angelini Industries one of the
Italian companies of excellence in the sectors in which it
operates. To learn more visit www.angeliniindustries.com.
About Angelini Pharma Angelini
Pharma is an international pharmaceutical company, part of the
Italian privately-owned multi-business Angelini Industries. The
Company researches, develops and commercializes health solutions
with a focus on the areas of Brain Health, including Mental Health
and Epilepsy, and Consumer Health. Founded in Italy at the
beginning of the 20th century, Angelini Pharma operates directly in
20 countries, employing more than 3,000 people. Its products are
marketed in over 70 countries through strategic alliances with
leading international pharmaceutical groups. For more information
about Angelini Pharma please visit
https://www.angelinipharma.com
About Helsinn Helsinn is a
global pharmaceutical company that builds, manufactures, launches,
and commercializes products to improve the quality of life for
patients with cancer and chronic disease, with a focus on
supportive care, oncology and dermato-oncology. Helsinn,
headquartered in Lugano, Switzerland, has direct commercial
operations in the U.S. and an extensive network of long-standing
trusted partners enabling a commercial presence in more than 90
countries.
Established in 1976, Helsinn is a third-generation family-owned
company with broad pharmaceutical and technical expertise. Helsinn
is proud of its history of operating with great integrity, passion
and quality. The company is committed to continuously striving for
innovation for its patients and embracing sustainable growth as a
core element of its strategic vision.
To learn more about Helsinn, please visit www.helsinn.com or
follow us on Twitter and LinkedIn.
For more information: Helsinn Group
Media Contact:Sabrina Perucchi Microsoft Teams
Group Communication ManagerLugano, Switzerland Tel: +41 (0) 91
985 21 21 Email: Info-hhc@helsinn.com
Angelini Pharma Daniela PoggioExecutive
Director Global Communications and Patient AdvocacyTel: +39
3486558882
Chiara AntoniucciGlobal Media Relations ManagerTel: +39
3477133926